<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="189">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04966988</url>
  </required_header>
  <id_info>
    <org_study_id>2021 V 1.0</org_study_id>
    <nct_id>NCT04966988</nct_id>
  </id_info>
  <brief_title>Multimodal Imaging Evaluation and Prognostic Analysis of Cardiac Allograft Vasculopathy in Heart Transplantation</brief_title>
  <official_title>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xie Mingxing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Asia Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to (1) establish a system of multimodal imaging technology; (2) jointly apply&#xD;
      multimodal imaging technology to diagnose of cardiac allograft vasculopathy of heart&#xD;
      transplantation; (3) construct a multimodal imaging technology prediction model of adverse&#xD;
      events, screening the best non-invasive imaging prediction indicators.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enrolled 1000 HT patients, and the cardiac allograft vasculopathy will be&#xD;
      evaluated by multimodal imaging technology. The aim is to (1) establish a system of&#xD;
      multimodal imaging technology; (2) jointly apply multimodal imaging technology to diagnose of&#xD;
      cardiac allograft vasculopathy of heart transplantation; (3) construct a multimodal imaging&#xD;
      technology prediction model of adverse events, screening the best non-invasive imaging&#xD;
      prediction indicators.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>All cause death</measure>
    <time_frame>up to 10 year</time_frame>
    <description>All cause death after HT was obtained via telephone interview with family members; contact with his/her physicians; or hospital records</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events</measure>
    <time_frame>5 year and 10 year</time_frame>
    <description>Major adverse cardiac events after the inclusion of the study was obtained via telephone interview with family members; contact with his/her physicians; or hospital records</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Heart Transplant</condition>
  <arm_group>
    <arm_group_label>CAV 0(Not significant)</arm_group_label>
    <description>No detectable angiographic lesion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAV 1 (Mild)</arm_group_label>
    <description>Angiographic left main (LM) &lt;50%, or primary vessel with maximum lesion of &lt;70%, or any branch stenosis &lt;70% (including diffuse narrowing) without allograft dysfunction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAV 2 (Moderate)</arm_group_label>
    <description>Angiographic LM &lt;50%; a single primary vessel≥70%, or isolated branch stenosis ≥70% in branches</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAV 3 (Severe)</arm_group_label>
    <description>Angiographic LM≥50%, or two or more primary vessels ≥70% stenosis, or isolated branch stenosis≥70%in all 3 systems; or CAV1 or CAV2 with allograft dysfunction (defined as LVEF≤45% usually in the presence of regional wall motion abnormalities) or evidence of significant restrictive physiology</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All adult HT recipients were consecutive prospectively enrolled who underwent transthoracic&#xD;
        echocardiography for surveillance at their routine follow-up&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Heart transplantation after January 1st, 2015.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        •Age &lt; 18 years at the time of transplantation; Died within 48 h; Heart-lung&#xD;
        transplantation; Heart/kidney transplantation; Re-transplanted within 7 days after&#xD;
        transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ultrasound, Union Hospital, Wuhan, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Zhang, PhD</last_name>
    <phone>18907131488</phone>
    <email>zli429@hust.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shuangshuang Zhu, MD</last_name>
    <phone>15971428009</phone>
    <email>18846032209@163.com</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 10, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>Xie Mingxing</investigator_full_name>
    <investigator_title>MD, PhD,FACC, FAHA, FASE</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

